関連文献

Renoprotective effect of telmisartan in patients with chronic kidney disease.

Clin Exp Hypertens. 30(7): 662-672, 2008.PubMed

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

Clin Nephrol. 70(5): 385-392, 2008.PubMed

Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.

Diabetologia. 50(2): 490-492, 2007.PubMed

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Am J Med Sci. 333(6): 321-326, 2007.PubMed

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Am J Hypertens. 20(11): 1195-1201, 2007.PubMed

Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.

Clin Nephrol. 65(1): 1-6, 2006.PubMed

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.

Diabetes Metab Res Rev. 22(5): 385-389, 2006.PubMed

Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.

Am J Nephrol. 26(3): 276-280, 2006.PubMed

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.

Am J Nephrol. 26(1): 82-86, 2006.PubMed

Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.

TAm J Med Sci. 330(4): 161-165, 2005.PubMed